Idiosyncratic Drug Reactions
Idiosyncratic drug reactions are unpredictable, dose-independent adverse effects with immune or metabolic origins. They are a major challenge in drug safety.
## Overview
Idiosyncratic drug reactions (IDRs) are adverse effects that occur unpredictably in susceptible individuals, are not explained by the drug's known pharmacological action, and are generally not dose-dependent in the conventional sense. They account for approximately 6-10% of all adverse drug reactions and are a leading cause of drug withdrawal from the market.
## Distinguishing Features
Unlike dose-dependent (Type A) reactions, IDRs are rare (typically <1:1,000), have a variable latency period (days to months), do not occur in most patients at any dose, and may involve organs unrelated to the drug's target. They often resolve upon drug withdrawal and may recur more rapidly and severely upon rechallenge.
## Immune-Mediated Mechanisms
The **hapten hypothesis** proposes that reactive drug metabolites covalently bind to proteins, creating neoantigens recognized by the immune system. Penicillin allergy exemplifies this: the beta-lactam ring opens and binds to tissue proteins, triggering IgE-mediated responses.
The **danger hypothesis** adds that tissue damage (from infection, inflammation, or the drug itself) provides costimulatory signals necessary for immune activation. This explains why some IDRs occur preferentially during concurrent infections.
The **pharmacological interaction with immune receptors (p-i) hypothesis** suggests certain drugs bind directly to MHC molecules or T-cell receptors without covalent modification, triggering immune responses. HLA-B*57:01 and abacavir hypersensitivity is a validated example.
## Metabolic Idiosyncrasy
Some IDRs result from genetic variation in drug metabolism rather than immune activation. Individuals who are slow acetylators (NAT2 polymorphism) have increased risk of isoniazid hepatotoxicity due to accumulation of the toxic metabolite hydrazine. CYP2D6 poor metabolizers may experience codeine toxicity or therapeutic failure depending on the prodrug pathway.
## HLA-Associated Reactions
Strong HLA associations have enabled prospective screening:
- **HLA-B*57:01**: Abacavir hypersensitivity (screening mandatory)
- **HLA-B*15:02**: Carbamazepine-induced Stevens-Johnson syndrome (Southeast Asian populations)
- **HLA-B*58:01**: Allopurinol hypersensitivity
- **HLA-A*31:01**: Carbamazepine DRESS syndrome
## Clinical Examples
**Drug-induced SJS/TEN**: Allopurinol, carbamazepine, lamotrigine, and sulfonamides. Mortality reaches 30% for TEN. **DRESS syndrome** (Drug Reaction with Eosinophilia and Systemic Symptoms): Anticonvulsants, allopurinol, dapsone. Latency 2-8 weeks. **Agranulocytosis**: Clozapine (1-2%), metamizole, antithyroid drugs.
## Key Takeaways
- IDRs are unpredictable, rare, and often immune-mediated
- Hapten formation, danger signals, and direct p-i interaction explain different mechanisms
- HLA genotyping can predict and prevent specific IDRs (abacavir, carbamazepine)
- Metabolic polymorphisms contribute to non-immune idiosyncratic toxicity
- Rechallenge is generally contraindicated due to risk of severe recurrence